-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Down 2.4%
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Down 2.4%
Shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Get Rating) fell 2.4% during mid-day trading on Wednesday . The stock traded as low as $4.45 and last traded at $4.98. 7,351,853 shares traded hands during mid-day trading, an increase of 1,036% from the average session volume of 646,993 shares. The stock had previously closed at $5.10.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on QNRX. LADENBURG THALM/SH SH began coverage on Quoin Pharmaceuticals in a research note on Friday, May 6th. They issued a "buy" rating and a $25.00 price target for the company. Maxim Group cut their price target on Quoin Pharmaceuticals to $25.00 in a research note on Thursday, May 26th.
Get Quoin Pharmaceuticals alerts:Quoin Pharmaceuticals Stock Performance
The firm has a 50 day simple moving average of $6.04 and a two-hundred day simple moving average of $11.38.
Quoin Pharmaceuticals (NASDAQ:QNRX – Get Rating) last released its earnings results on Monday, May 23rd. The company reported ($2.50) earnings per share for the quarter. On average, equities analysts anticipate that Quoin Pharmaceuticals, Ltd. will post -6.5 EPS for the current fiscal year.Institutional Investors Weigh In On Quoin Pharmaceuticals
An institutional investor recently bought a new position in Quoin Pharmaceuticals stock. Virtu Financial LLC bought a new position in shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Get Rating) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 42,665 shares of the company's stock, valued at approximately $57,000. Virtu Financial LLC owned about 0.51% of Quoin Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 21.72% of the company's stock.
Quoin Pharmaceuticals Company Profile
(Get Rating)
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease.
Read More
- Get a free copy of the StockNews.com research report on Quoin Pharmaceuticals (QNRX)
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- The 2 Dow Stocks with Decade-Long Win Streaks on the Line
- Could Rite Aid Be an Acquisition Target, Again?
- The How And Why of Investing in Oil Stocks
- The How and Why of Investing in Gold Stocks
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Get Rating) fell 2.4% during mid-day trading on Wednesday . The stock traded as low as $4.45 and last traded at $4.98. 7,351,853 shares traded hands during mid-day trading, an increase of 1,036% from the average session volume of 646,993 shares. The stock had previously closed at $5.10.
纳斯达克股票代码:QNRX-GET评级周三午盘下跌2.4%。该股一度跌至4.45美元,最后报4.98美元。午盘成交量为7,351,853股,较646,993股的平均成交量增加1,036%。该股此前收盘价为5.10美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Several brokerages recently issued reports on QNRX. LADENBURG THALM/SH SH began coverage on Quoin Pharmaceuticals in a research note on Friday, May 6th. They issued a "buy" rating and a $25.00 price target for the company. Maxim Group cut their price target on Quoin Pharmaceuticals to $25.00 in a research note on Thursday, May 26th.
几家券商最近发布了关于QNRX的报告。拉登堡THALM/SH SH在5月6日星期五的一份研究报告中开始报道Quoin PharmPharmticals。他们对该公司的评级为“买入”,目标价为25美元。Maxim Group在5月26日星期四的一份研究报告中将Quoin PharmPharmticals的目标价下调至25.00美元。
Quoin Pharmaceuticals Stock Performance
Quoin制药类股表现
The firm has a 50 day simple moving average of $6.04 and a two-hundred day simple moving average of $11.38.
该公司的50日简单移动均线切入位在6.04美元,200日简单移动均线切入位在11.38美元。
Institutional Investors Weigh In On Quoin Pharmaceuticals
机构投资者看好Quoin制药公司
An institutional investor recently bought a new position in Quoin Pharmaceuticals stock. Virtu Financial LLC bought a new position in shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Get Rating) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 42,665 shares of the company's stock, valued at approximately $57,000. Virtu Financial LLC owned about 0.51% of Quoin Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 21.72% of the company's stock.
一家机构投资者最近买入了Quoin PharmPharmticals股票的新头寸。根据Virtu Financial LLC最近提交给美国证券交易委员会的13F文件,该公司在第一季度购买了Quoin PharmPharmticals,Ltd.(纳斯达克代码:QNRX-GET Rating)的新股票头寸。该机构投资者购买了42,665股该公司股票,价值约57,000美元。在最近的报告期结束时,Virtu Financial LLC拥有Quoin制药公司约0.51%的股份。机构投资者持有该公司21.72%的股份。
Quoin Pharmaceuticals Company Profile
Quoin制药公司简介
(Get Rating)
(获取评级)
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease.
Quoin PharmPharmticals,Ltd.是一家专业制药公司,专注于开发治疗罕见和孤儿疾病的产品。该公司的主导产品是QRX003,一种治疗Netherton综合征的外用洗剂。它还开发了用于治疗营养不良性大疱性表皮松解症的QRX004;以及治疗罕见皮肤病的QRX006。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Quoin Pharmaceuticals (QNRX)
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- The 2 Dow Stocks with Decade-Long Win Streaks on the Line
- Could Rite Aid Be an Acquisition Target, Again?
- The How And Why of Investing in Oil Stocks
- The How and Why of Investing in Gold Stocks
- 免费获取StockNews.com关于Quoin PharmPharmticals的研究报告(QNRX)
- 大型和小型石油和天然气类股盈利后反弹
- 连续十年上涨的两只道指股票
- Rite Aid会再次成为收购目标吗?
- 投资石油股票的方式和原因
- 投资黄金股票的方式和原因
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得Quoin PharmPharmticals Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Quoin制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧